StockData
ANTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

AN2 Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.37−0.01 (-0.30%)

Close on Oct 19, 2026

Market cap
$150.84M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 11, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 11, 2026After market close–––
Q1 FY2026
Ended Mar 31, 2026
May 11, 2026After market close–$-0.29–
Q4 FY2025
Ended Dec 31, 2025
Mar 17, 2026After market close–$-0.29–
Q3 FY2025
Ended Sep 30, 2025
Nov 12, 2025After market close–$-0.31–
Q4 FY2024
Ended Dec 31, 2024
Mar 25, 2025After market close–$-0.25–
Q3 FY2024
Ended Sep 30, 2024
Nov 13, 2024After market close–––
Q2 FY2024
Ended Jun 30, 2024
Aug 13, 2024After market close–––
Q1 FY2024
Ended Mar 31, 2024
May 14, 2024After market close–$-0.56–
Q4 FY2023
Ended Dec 31, 2023
Mar 28, 2024After market close–$-0.57–
Q3 FY2023
Ended Sep 30, 2023
Nov 9, 2023After market close–$-0.65–
Q2 FY2023
Ended Jun 30, 2023
Aug 10, 2023After market close–$-0.81–

Press releases

Announcements AN2 Therapeutics filed with the SEC